Mycophenolate Mofetil Dose Reduction for Gastrointestinal Intolerance is Associated With Increased Rates of Rejection in Heart Transplant Patients

Journal of Heart and Lung Transplantation

Volumn 27, Issue 1, 2008, Pages 72-77

  Galiwango, Paul J ^a   Delgado, Diego H ^a   Yan, Raymond ^a   Kozuszko, Stella ^a   Smith, Robert ^a   Rao, Vivek ^a   Ross, Heather J ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART GRAFT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; STUDENT T TEST;

FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; ONTARIO; PRODRUGS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 37549037849     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.10.012     Document Type: Article

References (18)

1. Taylor A., David O., Edwards A., et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-third Official Adult Heart Transplantation Report-2006. J Heart Lung Transplant 25 (2006) 869-879
2. Eisen H., and Ross H. Optimizing the immunosuppressive regimen in heart transplantation. J Heart Lung Transplant 23 (2004) S207-S213
3. International Society of Heart and Lung Transplantation Registries. http://www.ishlt.org/registries Accessed August 2007
4. Kobashigawa J., Miller L., Renlund D., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66 (1998) 507-515
5. Eisen H., Kobashigawa J., Keogh A., et al. Three year results of a randomized, double blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 245 (2005) 517-525
6. Taylor D.O., Edwards L.B., Mohacsi P.J., et al. The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report-2003. J Heart Lung Transplant 22 (2003) 616-624
7. Kaczmarek I., Bjoern E., Schmauss D., et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 25 (2006) 550-556
8. Kobashigawa J., and Patel J. Immunosuppression for heart transplantation: where are we now?. Nat Clin Pract Cardiovasc Med 3 (2006) 203-212
9. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil. Drug Safety 24 (2001) 645-663
10. Lindenfeld J., Miller G., Shakar S., et al. Drug therapy in the heart transplant recipient-Part II: immunosuppressive drugs. Circulation 110 (2004) 3858-3865
11. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 17 (2003) 200-205
12. Meiser B., Pfeiffer M., Schmidt D., et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 18 (1999) 143-149
13. Gajarski R., Crowley D., Zamberlan M., and Lake D. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: does the MPA level matter?. Am J Transplant 4 (2004) 1495-1500
14. Kobashigawa J., Renlund D., Gerosa G., et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, Myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplanted recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 25 (2006) 935-941
15. DeNofrio D., Loh E., Kao A., et al. Mycophenolic Acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 19 (2000) 1071-1076
16. Yamani M., Starling R., Goormastic M., et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 69 (2000) 2326-2330
17. Haley C.J., Staples M.A., Vorpahl J., et al. Analytical performance of an EMIT assay for mycophenolic acid plasma [abstract]. Clin Chem 43 suppl 6 (1997) S209
18. Mourad M., Wallemacq P., Konig J., et al. Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary?. Clin Pharmacokinet 41 (2002) 319-327